Gold(I) Biscarbene Complexes Derived from Vascular-Disrupting Combretastatin A-4 Address Different Targets and Show Antimetastatic Potential

The Marine Polyketide Myriaporone 3/4 Stalls Translation by Targeting the Elongation Phase

(2013) Yazh Muthukumar et al.   CHEMBIOCHEM

Synergistic “gold effects” of anti-vascular 4,5-diarylimidazol-2-ylidene gold(I) carbene complexes

(2013) Julienne Münzner et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs

(2012) Wukun Liu et al.   CHEMICAL SOCIETY REVIEWS

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

(2012) P. Nathan et al.   CLINICAL CANCER RESEARCH

N-Heterocyclic carbene metal complexes in medicinal chemistry

(2012) Luciano Oehninger et al.   DALTON TRANSACTIONS

Synthesis, Characterization, and in Vitro Studies of Bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) Complexes

(2012) Wukun Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs

(2011) Alberta Bergamo et al.   DALTON TRANSACTIONS

Gold(I)–NHC complexes of antitumoral diarylimidazoles: Structures, cellular uptake routes and anticancer activities

(2011) Leonard Kaps et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin and paclitaxel in patients with advanced cancer

(2010) G J Rustin et al.   BRITISH JOURNAL OF CANCER

Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours

(2010) B Nitzsche et al.   BRITISH JOURNAL OF CANCER

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

(2010) Dietmar W. Siemann   CANCER TREATMENT REVIEWS

Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting

(2010) Chrisostomi Gialeli et al.   FEBS Journal

4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles That Are Cytotoxic against Combretastatin A Resistant Tumor Cells and Vascular Disrupting in a Cisplatin Resistant Germ Cell Tumor Model

(2010) Rainer Schobert et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome

(2009) Colin J. Mooney et al.   THYROID

Cell responses regulated by early reorganization of actin cytoskeleton

(2008) E.A. Papakonstanti et al.   FEBS LETTERS